EvaThera

[EvaThera @EvaThera]

https://t.co/Fd3JJJySrA

[EvaThera @EvaThera]

Molecular Targeting Technologies Reports Clinical Data Supporting Two-Cycle EBTATE and Enhanced Tumor Targeting in GEP-NET Patients at SNMMI 2026. https://t.co/037IiruOgv

[EvaThera @EvaThera]

@DrNeilStone Just go into the site no problem

[EvaThera @EvaThera]

MTTI at the 2nd Annual Targeted Radionuclide Pharmaceuticals Supply Chain & Manufacturing Summit
https://t.co/ZhnTX4nNga

[EvaThera @EvaThera]

MTTI reports on fast-acting sprayable molecule to visualize tumors for real-time fluorescence-guided cytoreductive surgery
https://t.co/ZhnTX4nNga

[EvaThera @EvaThera]

MTTI reports on 225Ac-EBTATE and 177Lu-EBTATE radiopharmaceuticals at 2024 Society of Nuclear Medicine and Molecular Imaging annual meeting
https://t.co/kQuJPOcq6l

[EvaThera @EvaThera]

Molecular Targeting Technologies, Inc. TO PRESENT EVATHERA, LONG-ACTING PEPTIDE RECEPTOR RADIONUCLIDE THERAPY PLATFORM, AT BIOFUTURE™ 2023
https://t.co/7LcQEV935m

[EvaThera @EvaThera]

MTTI ANNOUNCES THE APPOINTMENT OF DR. JERRY HUANG TO THE CLINICAL TEAM
https://t.co/8FlTohUVms

[EvaThera @EvaThera]

Molecular Targeting Technologies, Inc. and Molecular Theranostics Center of Singapore receive HSA approval for Clinical Trial Authorization for EBTATE® in Nasopharyngeal Cancer
https://t.co/ijQYiSMHMe

[EvaThera @EvaThera]

MTTI Highlights Promising One-Year Follow-Up On Ebtate Treatment Of Neuroendocrine Cancer Patients Without Amino Acid Infusion
https://t.co/kZXPhA9N8n

[EvaThera @EvaThera]

MTTI Annouces Favorable Three-Year Follow-Up For Ebtate In Neuroendocrine Tumors
https://t.co/LIt8q4U3Jd

[EvaThera @EvaThera]

MTTI Receives Chinese Patent for EVATHERA Technology
https://t.co/AtOebRAkB0

[EvaThera @EvaThera]

MTTI obtains FDA allowance of Investigational New Drug (IND) for Hürthle Cell Thyroid
Cancer
https://t.co/7BdNkyZHTg

[EvaThera @EvaThera]

MTTI will be exhibiting at SNMMI in-person this year and look forward to discussing our new EvaThera platform with you at our booth (#1715). While there, we invite you to learn more about MTTI, our technology, and the multiple clinical trials we are orchestrating.

[EvaThera @EvaThera]

Molecular Targeting Technologies, Inc., Thomas Jefferson University
and North China Pharmaceutical Co., Ltd announced the Chinese
approval for a Rabies drug
https://t.co/Cs6K6vp81C

[EvaThera @EvaThera]

MTTI and Monrol have signed a clinical supply agreement for Lu-177 n.c.a.
https://t.co/2nrQf55Wjs

[EvaThera @EvaThera]

MTTI partners with Evergreen to manufacture
EvaThera platform of radiopharmaceuticals
https://t.co/mjncOeCTEp

[EvaThera @EvaThera]

Molecular Targeting Technologies, Inc. Announces Spray Technology That Lights Up Tumors
https://t.co/nv9u9W7QIU

[EvaThera @EvaThera]

Molecular Targeting Technologies, Inc. and Temple University Announced Patent
approval for Anti-thrombotic Agents
https://t.co/Hzvbgh53u5

[EvaThera @EvaThera]

SNMMI was a great venue to launch our EvaThera site! Thank you to everyone that visited our booth.

In case you missed us and would like information about our new EvaThera Theranostic Platform, download our brochure! https://t.co/F1YrKzvCcD